Stephanie Brown, the SVP of rare diseases at Ipsen Biopharmaceuticals, describes the company’s involvement with the International Fibrodysplasia Ossificans Progressiva Association (IFOPA).
“It’s so inspiring to recently attend the Family Gathering, which is an annual event for the IFOPA,” Brown said. “It was inspiring to see patients, their families, caregivers, healthcare practitioners all working together to find solutions for these challenging conditions.”
Ipsen develops and markets medications used in oncology, neuroscience and rare diseases, as well as consumer healthcare products.
In September, the company shared data from its growing Rare Diseases Therapeutic Area portfolio at the American Society for Bone and Mineral Research (ASBMR) annual meeting. This included the oral presentation of Ipsen’s MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP). The data, presented by Robert Pignolo, MD, of the Mayo Clinic, describes the trial outcomes of the oral investigational therapy palovarotene in reducing new heterotopic ossification (HO) volume in 107 pediatric and adult patients with FOP. The MOVE efficacy results were compared with data from untreated patients from Ipsen’s Natural History Study (NHS).
Learn more about FOP and other rare bone diseases.
